Company
Headquarters: South San Francisco, CA, United States
Employees: 188
CEO: Ms. Elizabeth Homans
$615.6 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $130,000 |
| EBITDA | $-225,248,992 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -454392.33% |
| Quarterly Revenue Growth | -100.00% |
Lyell Immunopharma, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LYEL wb_incandescent